The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00408-011-9332-1.pdf
Reference23 articles.
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
2. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150
3. Felip E, Rosell R, Pampaloni G (2008) Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 4:579–585
4. Russo FBA, Pampaloni G (2008) Pemetrexed single agent chemotherapy in previously treated patients with local advanced or metastatic non small cell lung cancer. BMC Cancer 8:216–223
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer;BMC Medicine;2016-01-20
2. Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials;OncoTargets and Therapy;2015-10
3. The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials;OncoTargets and Therapy;2015-08
4. Regulation of vascular endothelial growth factor in prostate cancer;Endocrine-Related Cancer;2015-04-13
5. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib;European Journal of Clinical Pharmacology;2015-03-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3